TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) Meeting Abstract
| Authors: | Abida, W.; Bryce, A. H.; Balar, A. V.; Chatta, G. S.; Dawson, N. A.; Guancial, E. A.; Hussain, A.; Jha, G. G.; Lipsitz, D. U.; Patnaik, A.; Petrylak, D. P.; Ryan, C. J.; Stanton, T. S.; Vogelzang, N. J.; Zhang, J.; Simmons, A.; Go, J.; Golsorkhi, T.; Chowdhury, S.; Scher, H. I. |
| Abstract Title: | TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) |
| Meeting Title: | 2018 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2018 Feb 8-10 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-20 |
| Language: | English |
| ACCESSION: | WOS:000436179500382 |
| DOI: | 10.1200/JCO.2018.36.6_suppl.TPS388 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS388 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
